Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Follicum has announced that the company's hair loss treatment projects are progressing according to plan and a patent application for an internally developed formulation of FOL-005 has been submitted. The cream formulation is intended to be lubricated into the scalp and has demonstrated good hair-stimulating effect in an animal model.

Follicum files patent application for new topical formulation for hair loss

The next step involves running a clinical Phase II study in alopecia patients, which is expected to start at the end of 2019. If granted, the patent application would extend the patent protection of FOL-005 by 8 years.

The new cream formulation has been developed In parallel with the clinical program of FOL-005. In previous clinical studies in alopecia patients, FOL-005 has been dosed by injecting a solution of the peptide locally, up to three times per week. In the first study, FOL-005 was injected into the thigh of healthy volunteers and in the second study, the peptide was injected onto the scalp of alopecia patients.

In both studies, positive effects on hair growth were demonstrated. The new formulation, which has been tested in an experimental animal model and showed good hair stimulating properties, will be studied in a new clinical study planned to begin at the end of 2019. Preparations for this study and discussions with authorities are currently underway. With the new formulation, it will be possible to study several different doses and increase the dosage frequency in a simple way, since the individual patient will take care of the treatment at home. This simplifies the study and means that the number of visits to the clinic during the study period will be minimized.

CEO Jan Alenfall comments: “We are very pleased to have developed a formulation of FOL-005 that the patient can use in a simple way. The challenges of developing functional topical formulations of peptides are to prevent the peptide from breaking down and to optimize the conditions for it to penetrate the skin. We have managed to meet these challenges with the new formulation which has a long shelf life and is easy and very attractive for the patient to use. This has given us the confidence to file a new patent application.”

Read More

Related news

Funding to accelerate delivery of Univercells' vaccine portfolio

Funding to accelerate delivery of Univercells' vaccine portfolio

11 Oct 2019

European financing to support Univercells’ R&D investments to develop four essential and undersupplied global health vaccines to be produced at affordable prices, high quality and large volumes.

Read more 
Industrial-scale manufacture of therapeutic exosomes

Industrial-scale manufacture of therapeutic exosomes

10 Oct 2019

Coordinated purification process development service accelerates progress to clinical trials, and scale-up manufacturing.

Read more 
BASF and Biomillenia join forces in microbiome research to promote healthy skin

BASF and Biomillenia join forces in microbiome research to promote healthy skin

7 Oct 2019

Research aims to identify novel dermocosmetic active ingredients via unique microbiome-on-a-chip technology.

Read more 
Arctoris secures funding to advance novel robotic drug discovery platform

Arctoris secures funding to advance novel robotic drug discovery platform

1 Oct 2019

Platform will enable scientists and biotechnology entrepreneurs worldwide to make discoveries faster and more efficiently,

Read more 
Data on lead ADC demonstrates effective tumour regression

Data on lead ADC demonstrates effective tumour regression

1 Oct 2019

IKS01 shows marked anti-tumour efficacy in pre-clinical models of ovarian and lung cancer.

Read more 
Researchers develop less toxic anti-cancer drug

Researchers develop less toxic anti-cancer drug

24 Sep 2019

New drug works like a ‘magic bullet’ that is delivered directly to the mitochondria of cancer cells.

Read more 
EC approves its first plant-derived cannabis-based medicine

EC approves its first plant-derived cannabis-based medicine

24 Sep 2019

Epidyolex (cannabidiol) approved for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy.

Read more 
Study demonstrates potential of blood test for early lung cancer detection

Study demonstrates potential of blood test for early lung cancer detection

16 Sep 2019

Ground-breaking trial demonstrates potential of blood test which harnesses the power of the immune system to reduce late detection of lung cancer.

Read more 
M2i Life Sciences completes a historic fundraising of 60 million Euros

M2i Life Sciences completes a historic fundraising of 60 million Euros

16 Sep 2019

To support its strong growth, M2i Life Sciences has concluded a capital increase of 60 million Euros with five leading investors (ADM Capital, Eurazeo Growth, Téthys Invest, Creadev and France 2i fund managed by RAISE Impact).

Read more 
FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

FUJIFILM Irvine Scientific launches BalanCD Gal Supplement for biotherapeutic development

10 Sep 2019

Delivers enhanced galactosylation for improved protein quality, and antibody binding and function.

Read more